objeCtives: Use of surrogate endpoints like progression-free survival (PFS) and time to progression (TTP) instead of overall survival (OS) in clinical trials for advanced cancer remains challenging from a health economic standpoint. This study assessed the use of surrogate endpoints in economic evaluations of anticancer drugs and methodological approaches adopted when reliable OS data are unavailable. Methods: A systematic literature review was conducted to identify economic evaluations of treatments for advanced cancer published between January 2003 and October 2013. Cost-effectiveness and cost-utility analyses expressed in terms of cost per life-year gained and cost per quality-adjusted life-year using a surrogate endpoint as an outcome measure were eligible. Characteristics of selected studies were extracted and comprised: population, treatment of interest, comparator, line-of-treatment, study perspective, and time horizon. Use of surrogate endpoints and methods adopted when OS data were lacking were analyzed. Two reviewers independently selected studies and extracted data. Results: In total, 7,219 studies were identified and 100 fulfilled the eligibility criteria. Most included studies assessed the cost-effectiveness of a biological therapy (65%) in the first-line setting (56%) and in the context of advanced non-small cell lung cancer (24%) or advanced breast cancer (22%). Surrogate endpoints mostly used were PFS and TTP, accounting for 92% of included studies. OS data were unavailable for analysis in nearly 25% of economic evaluations. In the absence of OS data, studies most commonly assumed an equal risk of death for all treatment groups. Other methods included use of indirect comparison based on numerous assumptions, use of a surrogate endpoint as a proxy for OS, consultation with clinical experts, and use of OS data associated with different patient populations or treatment-line. ConClusions: Although several approaches are used, there is no consensus method to estimate the cost-effectiveness of new anticancer drugs in the absence of reliable OS data. (MM). Methods: Telephone interviews lasting approximately 1 hour were conducted with two HTA experts from each country, based on an interview guide. Interviews were recorded and common themes identified from assessment of the narrative. Results: The French advisors considered that the cost savings realized through informal care compared with formal caregiving are neglected, and that data on informal caregiver burden should be incorporated into cost-effectiveness models where available. The German advisors suggested that caregiver burden may be recognized in HTA if it can be related to patient benefit. Discussions in this area are increasing but changes to the acceptability of caregiver burden data was mostly likely to occur elsewhere in the healthcare system (i.e., outside of the benefit assessment process). Advisors in the US reported that payers' views of caregiver burden are changing and that this information should be considered as more patients involve their caregivers in decision-making, or caregivers make the decisions (for some groups of patients). ConClusions: Informal caregiver burden data are not currently considered important in HTA in Europe or the US, although there are suggestions that this may change. Even where such data have been included in HTA submissions, they have not generally been a driver of HTA decision-making. objeCtives: Data from real-world European settings describing treatment patterns and outcomes in relapsed/refractory multiple myeloma (RRMM) are limited. This study helps address this knowledge gap using a brief physician survey. Methods: Sixty-one physicians treating RRMM were surveyed (November 2014) in France (n= 21), Germany (n= 20), and the United Kingdom (UK) (n= 20). The survey collected physicians' opinions on typical treatment patterns and outcomes of RRMM patients in the relapse/refractory setting (following disease progression during/after firstline therapy). Analyses were descriptive. Results: Sixty percent of physicians in France and the UK were haematologists, versus 10% in Germany (where 80% were onco-haematologists). The proportion of patients with high-risk disease based on ISS stage and cytogenetics was 18%-24% across countries. Bortezomib/thalidomide/ dexamethasone was the most common induction regimen (42%) for stem cell transplant (SCT)-eligible patients in France, but was unused in Germany and less commonly prescribed in the UK (17%); bortezomib/cyclophosphamide/dexamethasone was the reported induction therapy for 28% of SCT-eligible patients in all countries. Regardless of SCT status, lenalidomide/dexamethasone was the predominant second-line treatment (37%-48%) reported in France and Germany; in the UK, second-/later-line regimens were more varied, with both lenalidomide-and bortezomib-based regimens being reported as common. Second-/later-line therapy duration was generally short, particularly in the UK where 75% of physicians reported a < 6-month duration. Disease progression was the top reason for second/laterline discontinuation; other common reasons included toxicity and completion of planned therapy course. For high-risk patients, > 75% of physicians reported median survival of < 1 year from first relapse. ConClusions: The proportion of RRMM patients with high-risk disease in real-world settings (18%-24%) may exceed that reported in clinical trials (10%-15%). Second-/later-line therapy duration is typically short (< 6 months). Survival prospects for RRMM patients remain limited, particularly for high-risk patients. Patient-level studies are needed to better characterize the unmet needs in RRMM signaled by our findings. Adult patients or parents of children completed a baseline survey that collected information regarding socio-demographics, clinical characteristics, and treatment patterns. During the two-year observation period, bleeding episodes were collected through regular patient follow-ups. ABF was calculated as the annualized sum of patient-reported bleeding episodes. Two-year drug dispensing information was also recorded and annualized. Multivariable linear regressions were used to assess the association of patient variables with ABF. Results: Of 477 recruited patients, 317 with complete baseline and utilization data and at least three months of patient follow-up were included. Among included patients, 49.8% were children, 39.7% used prophylaxis, and 63.1% had severe hemophilia. Variables significantly associated with ABF included 37 or older vs. 2-9 years of age (p= 0.03), married or with a partner (p= 0.03), hemophilia B (p= 0.09), mild/moderate hemophilia (p= 0.01), prophylaxis (p< 0.01), human immunodeficiency virus (HIV) (p< 0.01), hepatitis C virus (HCV) (p< 0.01), and annual factor usage per kilogram of body weight (p< 0.01). Among adults, age in years (p= 0.07), no insurance vs. public insurance (p= 0.04), mild/mod-
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PRM6 THE ACCEPTANCE Of MORbIDITy ENDPOINTS IN THE AMNOg PROCESS IN gERMANy: ARE THERE gREATER HURDlES fOR SUbSTANCES wITHIN ONCOlOgy?
Bakker K, Volmer T SmartStep Consulting GmbH, Hamburg, Germany objeCtives: The objective of this study is to assess the acceptance of morbidity endpoints by the Institute for Quality and Efficiency in Healthcare (IQWiG) within the early benefit assessment in Germany. The analysis focuses on morbidity endpoints (ME) for oncology substances compared to non-oncology substances: (1) how many ME have been accepted? (2) In how many cases has IQWiG determined an additional benefit based on ME? Methods: All benefit assessments published by the Federal Joint Committee (G-BA) between 01/01/2011 and 12/05/2015 have been considered (n= 126). Of those, 80 were excluded from the analysis due to one of the following reasons: orphan drug designation, no dossier submitted or incomplete evaluation by the IQWiG (due to missing data). Data analyzed: number of accepted ME as proportion of all submitted endpoints; additional benefit based on accepted ME; percent of assessments in which at least one ME was accepted. Results: In total, 19 oncology and 27 non-oncology assessments have been included into the analysis. For the 19 oncology assessments, a total of 76 ME had been submitted. IQWiG accepted hereof 20 ME (≈26%). Accepted ME include: pain, skeletal-related complications and symptoms. The IQWiG determined an additional benefit for six assessments based on ME (6/19≈32%). For the 27 non-oncology assessments, 127 ME had been submitted. IQWiG accepted 79 (≈62%) including: strokes, cardiovascular events and relapse-related events. For non-oncology substances, IQWiG determined an additional benefit for thirteen assessments based on ME (13/27≈48%). At least one endpoint was accepted in 83% of oncology assessments and in 100% of benefit assessments in all other indications. ConClusions: Though the rate of accepting ME in oncology indications is numerically lower (32% vs. 48%), the difference does not reach statistical significance (p= 0.36 Fisher's exact test). objeCtives: Multiple myeloma patients often experience adverse events (AEs) related to treatment with novel therapies or traditional chemotherapy. Observational studies frequently use administrative claims data or electronic medical records (EMR) to assess potential AEs. The purpose of this analysis is to compare the occurrence of AEs identified in claims data with those recorded in an oncology EMR. Methods: Multiple myeloma cases (n= 278) in the MarketScan Oncology EMR-Claims Linked Dataset who received novel or traditional chemotherapy were included. The index date was the first date of medication administration/order and patients were followed for AEs, including neutropenia, thrombocytopenia, venous thromboembolism (VTE) and diarrhea, until a > = 90 gap in all medications for the first regimen. Results: Neutropenia and thrombocytopenia were recorded less often in claims (neutropenia 9%; thrombocytopenia 7%) compared to EMR data (neutropenia 12%; thrombocytopenia 11%). Neutropenia and thrombocytopenia are monitored by oncologists with lab values and this may lead to more frequent recording of less severe AEs in the EMR not reflected in claims data. VTE and diarrhea were recorded more often in the claims (VTE 9%; diarrhea 7%) compared to the EMR (VTE 4%; diarrhea 4%). A VTE diagnosis may likely result in hospitalization and patients with diarrhea may seek care outside of their oncology practice; hence, claims data may capture additional diagnoses assigned by clinicians other than oncologists. Overall, the highest proportions of AEs were found with the linked data containing both the claims and EMR (neutropenia 19%, thrombocytopenia 16%, VTE 10%, diarrhea 11%). ConClusions: AEs typically monitored by lab values ordered by oncologists were recorded more often in EMR data and AEs potentially diagnosed by clinicians in settings outside the oncology practice were recorded more often in the claims data. The linked claims-EMR data provided the most complete assessment of potential treatment-related AEs. objeCtives: There is a growing call for the use of endonodal trials within network meta-analyses (NMA), such as for informative priors or improved connectivity. Endonodal trials can also be used to further inform arm-specific meta-regression coefficients, which may be used to simplify node definitions in combination therapy. We applied this concept to a network of first line antiretroviral therapy (ART) to determine if efavirenz (EFV) still belongs in the preferred regimen. Methods: We conducted a systematic search of electronic databases up to March 1, 2015. Nodes were defined as specific antivirals rather than ART regimens, which simplified interpretation of modeling and results. Backbone regimens were categorized and arm-specific meta-regression used to adjust estimates accordingly. The alternative approach was to simply reduce the evidence base to trials that did not differ with respect to backbones. The most notable trial to differ in backbones was the SINGLE trial comparing EFV to dolutegravir (DTG), central to the research question. Results: A total of 71 trials with 35,270 randomized patients informed the evidence base. DTG was found to be superior with respect to viral suppression at all time points (odds ratio objeCtives: The decision to utilize a particular product may depend on formal hospital guidelines, physician practice patterns, negotiated reimbursement schedules with insurance companies, and other local (geographic and/or hospital) characteristics. These elements are mostly unobservable for the purpose of statistical inference. A hospital fixed-effects model specification, in essence, controls for unobservable within-hospital time-invariant characteristics. Focusing on the relationship between iso-osmolar contrast media (CM) and low-osmolar CM agents (LOCM) and renal failure events in patients undergoing inpatient interventional procedures, this study highlights the importance of controlling for such factors by comparing statistical specifications with and without hospital fixedeffects. Methods: The Premier database was used to identify patients between January 2008 and September 2013. Eligible patients had a primary procedure of angioplasty defined by International Classification of Diseases, 9th Revision (ICD-9) and/or Current Procedural Terminology (CPT®) codes, inpatient admission, and LOCM or iso-osmolar CM agent. Renal failure during the visit was determined by ICD-9 diagnosis codes. Two different statistical approaches were employed to assess the relationship between renal failure and CM use -Ordinary Least Squares (OLS) cross-sectional and hospital fixed-effects model specification. Results: A total of 385,290 interventional procedure visits met the inclusion criteria. The unadjusted univariate analysis showed 1.7% (p< 0.01) more renal events in the iso-osmolar CM cohort compared to LOCM. The most saturated (OLS) cross-sectional analysis showed 1.4% (p< 0.01) fewer renal events in the iso-osmolar CM cohort compared to patients who received LOCM. Controlling for unobserved heterogeneity across hospitals using the most saturated hospital fixed-effect specification, we found 2.3% (p < 0.01) fewer renal failure events with iso-osmolar CM. ConClusions: This study illustrated the importance of controlling for observable and for unobservable, within-hospital time invariant characteristics through a hospital fixed-effects specification when the decision-making factors for selection of CM may vary from hospital to hospital. objeCtives: Alzheimer's disease (AD), the most common form of dementia, is a degenerative disorder of the brain that leads to memory loss. Oxidative stress is a hallmark of AD. This study aims to identify the genetic alterations of AD by using the conventional cytogenetic technique by Trypsin G-banding and molecular analysis of presenilin 1 (PS1) genotype by PCR. The role of selected ions related to energy metabolism as a consequence of oxidative stress in the deterioration accompanied in AD patients were also analyzed. Methods: The present study includes 49 AD patients and the subjects were categorized in two groups (14 Early-Onset AD) patients and (31 Late-Onset AD) patients, in order to investigate the possible cytogenetic and molecular damage. The gels were developed by staining with silver nitrate. Results: The Late-Onset AD patient shows higher total CA level when compared to Early-Onset AD patient. A comparison of the frequencies for PS1 genotypes among the Early-Onset AD and Late-Onset AD subjects demonstrated a significant difference between the two groups. ConClusions: The strong association of PS1 with Late-Onset AD patients called attention to the importance of genetic studies in AD and the possible roles of PS1 in the progression of this disease. Based on the contributing effects of PS1 in AD pathogenesis, targeting PS1 may provide new opportunities for AD therapeutic strategies. objeCtives: To compare physicians and patient's reports of health resource utilisation using the PGRx-3 datasets. Methods: PGRx (Pharmacoepidemiologic General Research eXtension) is a multiusers, multi-countries, prospective Real World Datasets originally assembled for effectiveness and relative risk of medicines research. In 2015, PGRx was extended to HEOR research in six countries (France, UK, Italy, Germany, Spain and in the US). Diseases studied with the PGRx methodology are: acute coronary syndrome, arrhythmias, stroke, lupus, rheumatoid arthritis, multiple sclerosis, Guillain Barré Syndrome, type I diabetes, autoimmune thyroiditis, depression and suicide attempts, paediatric autoimmune disorders, breast cancer, prostate cancer (on-going) and others. Patients are recruited by boardcertified specialists or general practitioners and they can fill self-questionnaires. More than 65% consenting patients also undergo a telephone interview. All PGRx datasets are submitted for ethics and privacy protection committees' approval in the contemplated countries. Medical records of more than 5,000 patients have been obtained in a series of validation studies including several of the PGRx disorders and results compared to interviews of the same patients on health resources and drug utilisation. Results: An agreement superior to 95% between patients and their physician's medical records was observed for report of chronic drug use and vaccines, but the agreement was low (< 30%) for drugs available OTC or in the patients' pharmacy (eg: NSAIDs) and for patients' health resources utilisation (eg: physician visits) (agreement less than 25%). ConClusions: Physicians have poor knowledge of acute drug use and of health resource utilisation by patients. Patient interviews are more valid sources of information for health economics and outcomes research than chart reviews
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